1
The study included a 48-week double-blind period where patients were randomised to Tadalista 0.3 mg/kg, Tadalista 0.6 mg/kg, or placebo daily. Most patients in these three studies were responders to previous on-demand treatment with PDE5 inhibitors. In the primary efficacy studies of general populations, 81% of patients reported that Tadalista improved their erections as compared to 35% with place